Jamaica Gleaner

Marijuana and safe pregnancy: Study seeks answer, draws critics

-

PREGNANCY STARTED out rough for Leslie Siu. Morning sickness and migraines had her reeling and barely able to function at a demanding New York marketing job, so like the rising numbers of American mothers-to-be, she turned to marijuana.

“I was finally able to get out from under my work desk,” said Siu, who later started her own pot company and sells a marijuana-based spray, and says her daughter, now four, is thriving.

There’s no proof that cannabis can relieve morning sickness, and mainstream medicine advises against use in pregnancy because of studies suggesting it might cause premature birth, low birth weight and infant brain deficits. But the National Institute on Drug Abuse is pressing for more solid evidence. Many of those studies were in animals or complicate­d

by marijuana users’ other habits and lifestyles.

“I don’t want us to cry wolf,” said Dr Nora Volkow, the agency’s director. “We have to do these studies in a way that can identify risks.”

With nearly US$200,000 from her agency, University of Washington scientists in Seattle are seeking clearer answers in a new study investigat­ing potential effects on infants’ brains. The agency is supporting three similar studies in other states.

In Seattle, they’re enrolling pregnant women during their first trimester who are already using marijuana for morning sickness. Researcher­s don’t provide the pot, and the use of other drugs, tobacco and alcohol isn’t allowed. Infants will undergo brain scans at six months and will be compared with babies whose mothers didn’t use marijuana while pregnant.

For government and university authoritie­s, it’s worthy research that takes advantage of a booming trend. Recent data show the number of

pregnant US pot users has doubled since 2002, with seven per cent reporting recent use and higher rates in some states.

But some opponents of recreation­al marijuana who think the science is settled have complained to the university and the federal government, calling it bogus research that endorses drug use and needlessly endangers foetuses.

The criticism underscore­s the challenges of investigat­ing how drugs of any kind affect pregnant women and their offspring. “There are so many reasons NOT to study drugs – particular­ly fear of causing birth defects. But the results would be no studies of the drugs’ efficacy during pregnancy, or the risks to the foetus,” said Dr John Lantos, director of paediatric bioethics at Children’s Mercy hospital in Kansas City, Missouri. “It’s risky to do studies of potentiall­y risky drugs, but it’s risky not to do studies.”

Among the most tragic examples is thalidomid­e, a drug developed in Germany in the 1950s as a sedative. It was later widely promoted and prescribed to treat morning sickness, mostly in Western Europe and Canada, despite a lack of research in pregnant women. It soon became linked with severe birth defects and was removed from most markets by the early 1960s.

safety concerns

The US Food and Drug Administra­tion never approved thalidomid­e for morning sickness because of safety concerns. The agency has approved a synthetic version of THC, the part of marijuana that causes a high, for AIDS-related appetite loss and a similar drug for nausea caused by cancer drugs, but has not approved it for morning sickness.

Scientist Natalia Kleinhans is leading the University of Washington’s study, aiming to recruit 35 pregnant marijuana users and 35 pregnant women who did not use pot.

The marijuana users are asked to buy from licensed dealers and photograph it so researcher­s can

calculate the THC and CBD content, another compound that doesn’t cause a high. Participan­ts are paid US$300 but can quit using it any time and remain in the study.

Medical and recreation­al marijuana are legal in Washington state, and Kleinhans says women who use it for morning sickness are different from pregnant pot users in years past, who often did other drugs, smoked or drank.

“They’re making a choice that people might not agree with. But it’s not out of desperatio­n. It’s an informed choice,” said Kleinhans, a brain imaging specialist who studies the brain and behaviour.

Not adequately informed of risks

Study opponents contend that researcher­s are recruiting marijuana addicts, that payment encourages participan­ts to keep using, that women aren’t being adequately informed of risks, and that babies will be harmed by being tested. Researcher­s say MRI brain scans are safe and that infants will be tested while sleeping, so they won’t need potentiall­y risky sedatives.

While more than 30 states have legalised marijuana for medical and/or recreation­al use, opponents also note that the federal government still considers pot an illegal drug – a stance that scientists say has hampered research.

Dr Pat Marmion, an OB/GYN in southern Washington, says he helped coordinate efforts to file complaints with the university and the US Department of Health and Human Services, which oversees the National Institutes of Health. An HHS spokespers­on declined comment.

“We should be encouragin­g women who are pregnant to not use marijuana instead of incentivis­ing them to continue,” Marmion said.

Under US law, research that involves humans must be approved by review boards to make sure participan­ts’ rights and safety are protected.

Karen Moe, director of the university’s human subjects division, said authoritie­s there investigat­ed the critics’ concerns and concluded that most were unfounded. But, she said, they agreed to provide a handout on possible risks from marijuana use in pregnancy, not just links to similar informatio­n online, and also reworded recruitmen­t materials to clarify that participan­ts could quit using marijuana and still receive full payment.

“From our standpoint, the situation is essentiall­y resolved and the study is good to go,” Moe said.

The National Institute on Drug Abuse is providing almost US$1.5 million for three similar studies of marijuana use in pregnancy – at Washington University in St Louis, at the University of Denver, and at Kaiser Permanente in Northern California.

“One of the big arguments about why this is unethical is that we already know the answers. That is not true,” said Susan Weiss, who oversees outside research for the institute. “We’re living in this very large social experiment and we need to learn from it.”

 ??  ??
 ?? AP ?? In this Friday, July 26, 2019 photo, Leslie Siu poses for a portrait next to her cannabis spray products geared toward women on display in Groundswel­l dispensary in east Denver.
AP In this Friday, July 26, 2019 photo, Leslie Siu poses for a portrait next to her cannabis spray products geared toward women on display in Groundswel­l dispensary in east Denver.

Newspapers in English

Newspapers from Jamaica